29th & 30th March 2017
Chairpersons
 Head of the Immune Regulation and Tumour Immunotherapy Group UCL Cancer Institute London, UK |
 Scientific Director, Immunotherapy Platform; Professor, Department of Genitourinary Medical Oncology; Professor, Department of Immunology; Co-Director, Parker Institute for Cancer Immunotherapy, MD Anderson Cancer Center, Houston, TX, USA |
Please click here for a printable PDF version of this programme.
Please note that timings are provisional and subject to change.
Speaker Conflict of Interest forms are here
Confirmation of accreditation is here
Wednesday Morning
Scientific Session 1
08.00
Badge Collection and Coffee
09:00
Eradicating tumors using the immune system
Professor Robert Schreiber, PhD
Alumni Professor, Pathology and Immunology, Director, Center for Human Immunology and Immunotherapy Programs, Washington University, St. Louis, MO. USA
Professor Robert Schreiber, PhD
Alumni Professor, Pathology and Immunology, Director, Center for Human Immunology and Immunotherapy Programs, Washington University, St. Louis, MO. USA
09.30
Immune checkpoint in cancer therapy: New insights into mechanism
Dr James P. Allison
Department Chair, Department of Immunology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr James P. Allison
Department Chair, Department of Immunology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
10.00
From the clinic to the lab: Investigating mechanisms of response and resistance to immune checkpoint therapy
Dr Padmanee Sharma
Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Padmanee Sharma
Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
10.30
Panel Q&A
10:45
Coffee Break
11:15
Industry Symposium 1 (45 mins)
12:00
The affordability of the extraordinary
Professor Richard Sullivan
Director of the Institute of Cancer Policy and King’s Health Partners Integrated Cancer Centre Global Health Work, London, UK
Professor Richard Sullivan
Director of the Institute of Cancer Policy and King’s Health Partners Integrated Cancer Centre Global Health Work, London, UK
12:45
Lunch
Wednesday Afternoon
13:45
Industry Symposium 2 (45 mins)
Scientific Session 2
14:30
Targeting the cancer mutanome
Dr Alena Gros Vidal
Group Leader, Vall d’Hebron Institute of Oncology, Barcelona, Spain
Dr Alena Gros Vidal
Group Leader, Vall d’Hebron Institute of Oncology, Barcelona, Spain
15:00
Coffee Break
15.30
Radiation treatment and immunotherapy combinations to improve outcome for cancer patients
Professor Tim Illidge
Professor of Targeted Therapy and Oncology, Institute of Cancer Sciences, Faculty of Medical & Human Sciences, University of Manchester, Manchester, UK
Professor Tim Illidge
Professor of Targeted Therapy and Oncology, Institute of Cancer Sciences, Faculty of Medical & Human Sciences, University of Manchester, Manchester, UK
16.00
Molecular and epigenetic programs defining tumor-specific T cell dysfunction
Dr Andrea Schietinger
Principal Investigator, Assistant Member, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Dr Andrea Schietinger
Principal Investigator, Assistant Member, Memorial Sloan Kettering Cancer Center, New York, NY, USA
16.30
The tumor microenvironment and the dynamics of the immune response in human tumors
Dr Jerome Galon
Research Director, Integrative Cancer Immunology Laboratory, INSERM, Paris, France
Dr Jerome Galon
Research Director, Integrative Cancer Immunology Laboratory, INSERM, Paris, France
17.00
Panel Q&A
17:15
Close
Thursday Morning
08.00
Badge Collection and Coffee
Scientific Session 3 with The Lancet Oncology
08:30
Trends & Collaborations in the IO Space
Dr Ramy Ibrahim
VP and Head of R&D, Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
Dr Ramy Ibrahim
VP and Head of R&D, Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
09.00
Deciphering immune regulation and recognition at the tumour site
Dr Sergio Quezada
Head of the Immune Regulation and Tumour Immunotherapy group, UCL Cancer Institute, London, UK
Dr Sergio Quezada
Head of the Immune Regulation and Tumour Immunotherapy group, UCL Cancer Institute, London, UK
09.30
Immune biomarkers and measuring response
Professor Alexander MM Eggermont
Director General of Gustave Roussy Cancer Campus Grand Paris, Villejuif, France
Professor Alexander MM Eggermont
Director General of Gustave Roussy Cancer Campus Grand Paris, Villejuif, France
10.00
Immuno-oncolytic viruses as cancer therapies
Professor Alan Melcher
Professor of Translational Immunotherapy; Team Leader, Translational Immunotherapy Team, The Institute of Cancer Research, London, UK
Professor Alan Melcher
Professor of Translational Immunotherapy; Team Leader, Translational Immunotherapy Team, The Institute of Cancer Research, London, UK
10.30
Panel Q&A
10:45
Coffee Break
11:15
Industry Symposium 3 (45 mins)
Thursday Afternoon
Scientific Session 4
12:00
Immune-based therapies for childhood cancer
Professor Crystal Mackall
Professor, Pediatrics & Medicine; Associate Director, Stanford Cancer Institute, Stanford Medical School, Stanford, CA, USA
Professor Crystal Mackall
Professor, Pediatrics & Medicine; Associate Director, Stanford Cancer Institute, Stanford Medical School, Stanford, CA, USA
12:30
Lunch
13.30
Emerging approaches in melanoma immunotherapy
Dr Christian Blank
Group Leader at the Division of Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands
Dr Christian Blank
Group Leader at the Division of Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands
14.00
The interplay between panomics and immunotherapy to advance therapy
Professor Charles Swanton
Cancer Research UK Senior Clinical Research Fellow & Group Leader of the Translational Cancer Therapeutics Laboratory, UCL Cancer Institute and Francis Crick Institute, UK
Professor Charles Swanton
Cancer Research UK Senior Clinical Research Fellow & Group Leader of the Translational Cancer Therapeutics Laboratory, UCL Cancer Institute and Francis Crick Institute, UK
14:30
Coffee Break
15:00
New insights on the mechanisms regulating the synergy of radiotherapy with immune checkpoint inhibitors
Professor Sandra Demaria
Professor of Radiation Oncology and Pathology, Weill Cornell Medical College, New York, NY, USA
Professor Sandra Demaria
Professor of Radiation Oncology and Pathology, Weill Cornell Medical College, New York, NY, USA
15.30
Metabolic competition in the tumor microenvironment is a driver of cancer progression
Dr Erika Pearce
Director of the Institute; Head of the department of Immunometabolism, the Max Planck Institute of Immunobiology and Epigenetics, Freiberg, Germany
Dr Erika Pearce
Director of the Institute; Head of the department of Immunometabolism, the Max Planck Institute of Immunobiology and Epigenetics, Freiberg, Germany
16.00
Panel Q&A
Keynote Presentation
16.10
Ongoing development of checkpoint trials
Dr James Larkin
Consultant Medical Oncologist, The Royal Marsden Hospital, London, UK
Dr James Larkin
Consultant Medical Oncologist, The Royal Marsden Hospital, London, UK
16:55
Close
ACI is supported by sponsorship from the Pharmaceutical Industry.
As support agreements are reached, disclosure of the supporters is listed here.